KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Somatic mutations in the MAPK signaling pathway are common in acute myeloid leukemia (AML) at diagnosis.
• The prognostic impact of these mutations on treatment resistance and long-term outcomes in AML is not fully understood.

Purpose of the Study:

• To investigate the effect of MAPK pathway mutations, specifically KRAS mutations, on treatment outcomes in newly diagnosed AML.
• To evaluate the association between MAPK mutations and overall survival (OS), composite complete remission (CRc), and relapse-free survival (RFS) in AML patients.

Main Methods:

• Retrospective analysis of 74 newly diagnosed MAPK-mutated AML patients treated at a single institution.
• Logistic and Cox regression models were employed to assess survival and remission endpoints.
• Key factors analyzed included European LeukemiaNet 2022 risk stratification, KRAS mutation status, karyotype, and age.

Main Results:

• The 5-year overall survival (OS) for the cohort was 28.9%.
• KRAS mutation (HR: 2.14) and ELN 2022 adverse risk (HR: 3.56) were independently associated with inferior OS.
• Abnormal karyotype (OR: 0.25) and increasing age (OR: 0.97) correlated with decreased odds of achieving CRc.
• KRAS mutation negatively impacted OS and RFS but not CRc.

Conclusions:

• KRAS mutations in AML appear to confer adverse prognostic significance, impacting overall survival and relapse-free survival.
• These findings highlight the need for further validation in larger, multicenter studies to confirm the prognostic role of KRAS mutations in AML treatment.
• Understanding the impact of specific mutations like KRAS is crucial for refining risk stratification and treatment strategies in AML.